4523.T Eisai Co., Ltd.
¥4,631 -0.19%
Asia · Pharmaceuticals
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-0.19%
YTD
-1.80%
P/E
—
P/B
—
ROE
—
Div yield
—
Beta
0.03
Market cap
—
RSI (14)
41
Next earnings
—
Previous session
close of Oct 8, 2026 · EOD, no live order bookOpen
¥4,710
Close
¥4,631
VWAP (n/a)
—
Day high
¥4,728
Day low
¥4,571
Volume
1.1M
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
Yahoo Finance · Sep 28
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
Yahoo Finance · Sep 3
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
Yahoo Finance · Aug 31
Final CDA-AMC Recommendation Brings Canadians with Early-Stage Alzheimer's Disease One Step Closer to Accessing LEQEMBI® (lecanemab)
Yahoo Finance · Aug 31
Eisai (TSE:4523) Launches At Home LEQEMBI, Is The Stock 8% Overvalued?
Yahoo Finance · Aug 30
Leqembi Iqlik® for initiation treatment launched in the US
Yahoo Finance · Aug 24
Headlines via Yahoo Finance · links open the source · not an endorsement.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell 4523.T. Try it in the Lab to size a position and see the risk.